Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Junmaikang (adalimumab) post-marketing registry in Chinese pediatric moderate-to-severe Crohn's disease
CTR20242790Phase 4Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of adalimumab in Crohn's disease, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Sep 2024; status: active.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20242790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242790.